STOCK TITAN
  1. Home
  2. Sec-filings
  3. BDSX
  4. [8-K] BIODESIX INC Reports Material Event

Biodesix (Nasdaq: BDSX) grows Q2 2026 revenue 34% to $26.9M

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Biodesix, Inc. reported second-quarter 2026 results with total revenue of $26.9 million, a 34% year-over-year increase. Diagnostic Testing revenue was $25.4 million, up 42%, driven by 20,900 tests, a 38% volume increase and higher average revenue per test. Development Services revenue was $1.5 million, reflecting project timing.

Gross margin reached 82%, a 200-basis-point improvement. Operating expenses excluding direct costs were $27.4 million, up 7%. Net loss narrowed to $7.3 million, a 37% improvement, and Adjusted EBITDA loss improved to $3.2 million, a 56% improvement. Cash and cash equivalents were $30.0 million. Total assets were $95.3 million and stockholders’ equity improved to $9.1 million, up from a deficit at year-end 2025, while long-term notes payable were $46.8 million. Full-year 2026 revenue guidance remains $108–114 million, with the midpoint implying about 25% growth and maintaining gross margin of roughly 80% while progressing toward Adjusted EBITDA profitability.

Positive

  • Q2 2026 revenue rose 34% to $26.9 million, with Diagnostic Testing revenue up 42% and gross margin expanding to 82%.
  • Net loss improved to $7.3 million (37% better year over year) and Adjusted EBITDA loss narrowed to $3.2 million, a 56% improvement, while stockholders’ equity turned positive at $9.1 million.

Negative

  • Despite margin gains, Biodesix still reported a quarterly net loss of $7.3 million and negative Adjusted EBITDA of $3.2 million, indicating it has not yet achieved profitability.
  • Development Services revenue declined to $1.5 million in Q2 2026 from $2.1 million in the prior-year period, contributing less to overall growth.

Filing Explained

Net ATM proceeds increased cash, while common shares outstanding reached 10,549,890 by June 30, 2026, from 8,253,053 at year-end.

This Form 8-K reports Biodesix’s second-quarter results and related financial condition update for the period ended June 30, 2026. The company also reports $6.5 million of net proceeds from its at-the-market program and 10,549,890 common shares issued and outstanding at June 30, versus 8,253,053 at December 31, 2025, so the disclosure records added cash alongside a higher reported share count.

An at-the-market program permits an issuer to sell new shares gradually into the open market at prevailing prices. The filing identifies the $6.5 million as net proceeds already included in the quarter’s cash change; it does not state how many shares were sold through that program.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Total revenue Q2 2026 $26.9 million Three months ended June 30, 2026; 34% growth vs prior-year quarter.
Diagnostic Testing revenue Q2 2026 $25.4 million Q2 2026 Diagnostic Testing revenue; 42% year-over-year growth.
Gross margin Q2 2026 82% Gross margin for the second quarter 2026; 200-basis-point improvement vs prior year.
Net loss Q2 2026 $7.3 million Net loss for the quarter ended June 30, 2026; 37% improvement vs prior year.
Adjusted EBITDA Q2 2026 ($3.2 million) Adjusted EBITDA loss for Q2 2026; 56% improvement vs Q2 2025.
Cash and cash equivalents $30.0 million Cash and cash equivalents at June 30, 2026; management cites a 17% increase vs March 31, 2026.
FY 2026 revenue guidance $108–114 million Full-year 2026 total revenue outlook; midpoint implies ~25% growth over 2025.
Stockholders’ equity June 30, 2026 $9.1 million Stockholders’ equity at June 30, 2026, improved from a $2.5 million deficit at December 31, 2025.
Adjusted EBITDA financial
"Adjusted EBITDA was a loss of $3.2 million in the second quarter 2026"
Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.
Development Services financial
"Development Services revenue of $1.5 million in the second quarter 2026"
Operating lease right-of-use assets financial
"Operating lease right-of-use assets | | | 3,542 | | | | 2,997"
An operating lease right-of-use (ROU) asset is an accounting entry that shows the value of a leased item you have the legal right to use—like a building, vehicle, or equipment—recorded on a company’s balance sheet along with the corresponding lease obligation. Investors care because it adds to reported assets and liabilities, changing measures like leverage and return on assets much like bringing a long-term rental onto the company’s financial snapshot, which can affect credit terms and valuation.
warrant liability financial
"Change in fair value of warrant liability, net | | | — | | | | 98"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
Total revenue $26.9 million 34% increase vs Q2 2025
Diagnostic Testing revenue $25.4 million 42% increase vs Q2 2025
Gross margin 82% 200-basis-point improvement vs Q2 2025
Net loss ($7.3 million) 37% improvement vs Q2 2025
Adjusted EBITDA ($3.2 million) 56% improvement vs Q2 2025
Guidance

For full year 2026, Biodesix expects total revenue of $108–114 million, maintaining gross margin around 80% and continuing progress toward Adjusted EBITDA profitability.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What were Biodesix (BDSX) revenues in Q2 2026?
Biodesix reported Q2 2026 total revenue of $26.9 million, a 34% year-over-year increase. Diagnostic Testing revenue was $25.4 million, while Development Services contributed $1.5 million, reflecting timing of project completion and revenue recognition.

How profitable was Biodesix (BDSX) in Q2 2026?
Biodesix remained unprofitable, with a Q2 2026 net loss of $7.3 million, a 37% improvement year over year. Adjusted EBITDA was a loss of $3.2 million, a 56% improvement, supported by an 82% gross margin and slower growth in operating expenses.

What 2026 revenue guidance did Biodesix (BDSX) provide?
For full year 2026, Biodesix expects total revenue of $108–114 million, with the midpoint representing about 25% growth over 2025. The company plans to maintain gross margin around 80% and continue progressing toward Adjusted EBITDA profitability.

How did Biodesix (BDSX) diagnostic testing perform in Q2 2026?
Diagnostic Testing revenue reached $25.4 million in Q2 2026, up 42% year over year. Test volumes increased 38% to 20,900, and higher average revenue per test, driven by expanded payer coverage and revenue cycle improvements, further supported segment growth.

What is Biodesix (BDSX) cash and debt position as of June 30, 2026?
As of June 30, 2026, Biodesix held $30.0 million in cash and cash equivalents. Long-term notes payable were $46.8 million, and stockholders’ equity stood at $9.1 million, improving from a deficit at December 31, 2025.

Which non-GAAP measure does Biodesix (BDSX) emphasize and why?
Biodesix emphasizes Adjusted EBITDA as a key non-GAAP measure. Management uses it to assess operating performance, aid planning and forecasting, and compare results across periods by excluding interest, taxes, depreciation, amortization, share-based compensation, warrant revaluations, and other non-recurring items.
0001439725false00014397252026-08-052026-08-05

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

August 5, 2026
Date of Report (Date of earliest event reported)

Biodesix, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

001-39659

20-3986492

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

 

919 West Dillon Rd

Louisville, Colorado

(Address of Principal Executive Office)

80027

(Zip Code)

 

Registrant’s telephone number, including area code: (303) 417-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value of $0.001 per share

 

BDSX

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2026, Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The information contained in Item 2.02 to this Current Report on Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such document or filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

No.

 

Exhibit

99.1

 

Press Release issued by Biodesix, Inc. dated August 5, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 5, 2026

BIODESIX, INC.

 

 

 

 

By:

/s/ Robin Harper Cowie

 

Name:

Robin Harper Cowie

 

Title:

Chief Financial Officer

 

 

Exhibit 99.1

img189760734_0.jpg

Biodesix Announces Second Quarter 2026 Results and Highlights

Delivered $26.9 million in revenue, representing 34% growth in Q2 2026;

Achieved 82% gross margin in Q2 2026;

Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth;

Conference Call and Webcast Today at 4:30 p.m. ET

LOUISVILLE, CO, August 5, 2026 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2026.

“Biodesix delivered another strong quarter, highlighted by 34% revenue growth, 42% growth in Diagnostic Testing revenue, and gross margins, which increased to 82%,” said Scott Hutton, Chief Executive Officer. “Our performance reflects continued adoption of our blood-based lung diagnostics, expanding reimbursement coverage, and improving sales force productivity. Diagnostic testing volumes grew 38% year-over-year while operating expenses excluding direct costs increased only 7%, demonstrating meaningful operating leverage and a 56% improvement in Adjusted EBITDA.”

Hutton continued, “In delivering against our mission to conquer lung cancer and other diseases, we believe our combination of clinical evidence, reimbursement strength, commercial execution, and disciplined expense management positions Biodesix to continue delivering sustainable growth while advancing toward profitability.”

Business and Financial Highlights for the Second Quarter 2026

•
Diagnostic Testing revenue was $25.4 million in the second quarter, representing 42% growth, driven by a 38% increase in test volumes to 20,900 and higher average revenue per test year-over-year. The improvement in average revenue per test was primarily attributable to expanded payer coverage and continued improvements to revenue cycle management;
•
Development Services revenue of $1.5 million in the second quarter 2026, as compared to $2.1 million in the prior year period reflecting timing of project completion and revenue recognition. The Development Services pipeline is strong and supports expectations for growth over the remainder of 2026;
•
Total revenue of $26.9 million in the second quarter 2026, an increase of 34% over the respective prior year comparable period;
•
Gross margin was 82% in the second quarter, a 200-basis point improvement over the respective prior year comparable period. The Company continues to deliver strong gross margins driven by higher Diagnostic Testing volumes, improved average revenue per test, and continued optimization of laboratory workflows, resulting in a lower cost per test;
•
Operating expenses (excluding direct costs and expenses) of $27.4 million for the second quarter 2026, an increase of 7% over the respective prior year comparable period. The Company expects continued operating leverage as our expanded sales team gains experience, increases productivity, and delivers sustained performance;
o
Includes non-cash stock compensation expense of $0.8 million during the second quarter 2026, a decrease of 21% versus the respective prior year comparable period;
•
Net loss of $7.3 million for the second quarter 2026, an improvement of 37% over the respective prior year comparable period;

 

•
Adjusted EBITDA was a loss of $3.2 million in the second quarter 2026, a 56% improvement over the respective prior year comparable period;
•
Cash and cash equivalents of $30.0 million, an increase of 17% over the period ending March 31, 2026. Change in cash included $6.5 million of net proceeds from our at-the-market program. We believe current cash, expected growth in revenue, and ongoing operational leverage provide sufficient liquidity to execute our growth strategy.

2026 Financial Outlook

 

For full year 2026, the Company expects total revenue of $108–114 million, with the midpoint representing approximately 25% growth over 2025. Biodesix expects continued progress toward achieving and maintaining Adjusted EBITDA profitability, driven by increasing sales productivity, expanded clinical evidence supporting the Nodify Lung tests, growth in the Development Services pipeline, and demonstrated operating leverage.

 

Metric

FY 2026 Guidance

Total Revenue

$108-114M (mid-point is 25% growth)

Gross Margin

Maintain ~80%

Adj. EBITDA

Continued improvement on path to profitability

 

Conference call and webcast information

Listeners can register for the webcast via this link. Analysts who wish to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the Company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time.

For a full list of Biodesix press releases and webinars, please visit biodesix.com.

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including the Nodify Lung® Nodule Risk Assessment test and the IQLung® Cancer Treatment Guidance test, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Use of Non-GAAP Financial Measure

Biodesix reported results are presented in accordance with generally accepted accounting principles in the United States (GAAP).

Biodesix also presents Adjusted EBITDA, a non-GAAP financial measure, in this press release. Adjusted EBITDA is a key performance measure that our management uses to assess our financial performance, for internal planning and forecasting purposes, and as an additional measure of our performance for the purposes of business decision-making, including managing expenditures. We believe that this non-GAAP financial measure is useful to investors and other interested parties in analyzing our financial performance because it provides a comparable overview of our operations across historical periods, and helps our management identify additional trends in our financial results that may not be shown solely by period-to-period comparisons of Net loss or Loss from operations. In addition, we believe that providing Adjusted EBITDA, together with a reconciliation of Net loss to Adjusted EBITDA, helps investors make comparisons between our Company and other companies that may have different capital structures, different tax rates, and/or different forms of employee

 

compensation. Our management recognizes that Adjusted EBITDA has inherent limitations because of the excluded items and may not be directly comparable to similarly titled metrics used by other companies.

We calculate Adjusted EBITDA as Net loss adjusted to exclude interest, income tax expense, if any, depreciation and amortization, share-based compensation expense, loss on debt extinguishments, net, change in fair value of warrant liabilities, net, other income, net, and other non-recurring items. Non-recurring items are excluded as they are not representative of our underlying operating performance. Adjusted EBITDA should be viewed as a measure of operating performance that is a supplement to, and not a substitute for Loss from operations, Net loss, and other GAAP measures.

Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning possible or assumed future results of operations, including descriptions of our revenues, profitability, outlook, and overall business strategy, the timing and assumptions regarding collection of revenues on projections, availability of funds and future capital, the anticipated impact and benefits of new clinical data, reimbursement coverage and research partnerships, the impact of enhanced U.S. tariffs, import/export restrictions or other trade barriers on the company and its operations and financial performance. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of our most recent Annual Report on Form 10-K, filed February 26, 2026, or subsequent Quarterly Reports on Form 10-Q during 2026, as applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contacts:

Media:

Natalie St. Denis

natalie.stdenis@biodesix.com

(720) 925-9285

Investors:

Chris Brinzey

chris.brinzey@icrhealthcare.com

(339) 970-2843

 

 

Biodesix, Inc.

Condensed Balance Sheets (unaudited)

(in thousands, except share data)

 

 

 

June 30, 2026

 

 

December 31, 2025

 

Assets

 

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

$

29,996

 

 

$

18,987

 

Accounts receivable, net of allowance for credit losses of $117 and $62

 

 

9,113

 

 

 

9,036

 

Other current assets

 

 

4,456

 

 

 

4,495

 

Total current assets

 

 

43,565

 

 

 

32,518

 

Non‑current assets

 

 

 

 

 

 

Property and equipment, net

 

 

23,803

 

 

 

24,817

 

Intangible assets, net

 

 

2,979

 

 

 

3,883

 

Operating lease right-of-use assets

 

 

3,542

 

 

 

2,997

 

Goodwill

 

 

15,031

 

 

 

15,031

 

Other long-term assets

 

 

6,406

 

 

 

8,230

 

Total non‑current assets

 

 

51,761

 

 

 

54,958

 

Total assets

 

$

95,326

 

 

$

87,476

 

 

 

 

 

 

 

Liabilities and Stockholders' Equity (Deficit)

 

Current liabilities

 

 

 

 

 

 

Accounts payable

 

$

2,160

 

 

$

3,080

 

Accrued liabilities

 

 

10,411

 

 

 

11,033

 

Deferred revenue

 

 

205

 

 

 

961

 

Current portion of operating lease liabilities

 

 

1,609

 

 

 

1,364

 

Current portion of notes payable

 

 

—

 

 

 

6

 

Other current liabilities

 

 

906

 

 

 

992

 

Total current liabilities

 

 

15,291

 

 

 

17,436

 

Non‑current liabilities

 

 

 

 

 

 

Long‑term notes payable, net of current portion

 

 

46,817

 

 

 

47,445

 

Long-term operating lease liabilities

 

 

23,370

 

 

 

24,039

 

Other long-term liabilities

 

 

704

 

 

 

1,021

 

Total non‑current liabilities

 

 

70,891

 

 

 

72,505

 

Total liabilities

 

 

86,182

 

 

 

89,941

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity (deficit)

 

 

 

 

 

 

Preferred stock, $0.001 par value, 5,000,000 authorized;
    0 (2026 and 2025) issued and outstanding

 

 

—

 

 

 

—

 

Common stock, $0.001 par value, 200,000,000 authorized;
   10,549,890 (2026) and 8,253,053 (2025) shares issued and outstanding

 

 

11

 

 

 

8

 

Additional paid‑in capital

 

 

521,961

 

 

 

495,289

 

Accumulated deficit

 

 

(512,828

)

 

 

(497,762

)

Total stockholders’ equity (deficit)

 

 

9,144

 

 

 

(2,465

)

Total liabilities and stockholders’ equity (deficit)

 

$

95,326

 

 

$

87,476

 

 

 

Biodesix, Inc.

Condensed Statements of Operations (unaudited)

(in thousands, except per share data)

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenues

 

 

 

 

 

 

 

 

 

 

 

 

Diagnostic Tests

 

$

25,349

 

 

$

17,898

 

 

$

47,640

 

 

$

34,214

 

Development Services

 

 

1,512

 

 

 

2,120

 

 

 

4,776

 

 

 

3,762

 

Total revenues

 

 

26,861

 

 

 

20,018

 

 

 

52,416

 

 

 

37,976

 

Direct costs and expenses

 

 

4,820

 

 

 

4,031

 

 

 

9,025

 

 

 

7,734

 

Research and development

 

 

3,135

 

 

 

3,269

 

 

 

6,420

 

 

 

6,139

 

Sales, marketing, general and administrative

 

 

24,282

 

 

 

22,411

 

 

 

48,543

 

 

 

42,859

 

Impairment loss on intangible assets

 

 

12

 

 

 

26

 

 

 

17

 

 

 

99

 

Total operating expenses

 

 

32,249

 

 

 

29,737

 

 

 

64,005

 

 

 

56,831

 

Loss from operations

 

 

(5,388

)

 

 

(9,719

)

 

 

(11,589

)

 

 

(18,855

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(1,982

)

 

 

(1,898

)

 

 

(3,959

)

 

 

(3,583

)

Change in fair value of warrant liability, net

 

 

—

 

 

 

98

 

 

 

—

 

 

 

(280

)

Other income, net

 

 

97

 

 

 

51

 

 

 

482

 

 

 

149

 

Total other expense

 

 

(1,885

)

 

 

(1,749

)

 

 

(3,477

)

 

 

(3,714

)

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(7,273

)

 

$

(11,468

)

 

$

(15,066

)

 

$

(22,569

)

Net loss per share, basic and diluted

 

$

(0.71

)

 

$

(1.56

)

 

$

(1.51

)

 

$

(3.08

)

Weighted-average shares outstanding, basic and diluted

 

 

10,296

 

 

 

7,333

 

 

 

9,977

 

 

 

7,316

 

 

 

Biodesix, Inc.

Reconciliation of Net Loss to Adjusted EBITDA (unaudited)

(in thousands)

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Net loss

$

(7,273

)

 

$

(11,468

)

 

$

(15,066

)

 

$

(22,569

)

Interest expense

 

1,982

 

 

 

1,898

 

 

 

3,959

 

 

 

3,583

 

Depreciation and amortization

 

1,387

 

 

 

1,436

 

 

 

2,783

 

 

 

2,876

 

Share-based compensation expense

 

820

 

 

 

1,039

 

 

 

1,935

 

 

 

2,011

 

Change in fair value of warrant liability, net

 

—

 

 

 

(98

)

 

 

—

 

 

 

280

 

Other (income) expense, net

 

(97

)

 

 

(20

)

 

 

(846

)

 

 

410

 

Adjusted EBITDA

$

(3,181

)

 

$

(7,213

)

 

$

(7,235

)

 

$

(13,409

)

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents

Press Releases

Other Documents